Cargando…

Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study

BACKGROUND: In response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for children aged 14 months was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting individuals aged 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohm, Milou, Hahné, Susan J M, van der Ende, Arie, Sanders, Elisabeth A M, Berbers, Guy A M, Ruijs, Wilhelmina L M, van Sorge, Nina M, de Melker, Hester E, Knol, Mirjam J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258937/
https://www.ncbi.nlm.nih.gov/pubmed/34525199
http://dx.doi.org/10.1093/cid/ciab791
_version_ 1784741661933305856
author Ohm, Milou
Hahné, Susan J M
van der Ende, Arie
Sanders, Elisabeth A M
Berbers, Guy A M
Ruijs, Wilhelmina L M
van Sorge, Nina M
de Melker, Hester E
Knol, Mirjam J
author_facet Ohm, Milou
Hahné, Susan J M
van der Ende, Arie
Sanders, Elisabeth A M
Berbers, Guy A M
Ruijs, Wilhelmina L M
van Sorge, Nina M
de Melker, Hester E
Knol, Mirjam J
author_sort Ohm, Milou
collection PubMed
description BACKGROUND: In response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for children aged 14 months was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting individuals aged 14–18 years was executed. We investigated the impact of MenACWY vaccination implementation in 2018–2020 on incidence rates and estimated vaccine effectiveness (VE). METHODS: We extracted IMD cases diagnosed between July 2014 and December 2020 from the national surveillance system. We calculated age group–specific incidence rate ratios by comparing incidence rates before (July 2017–March 2018) and after (July 2019–March 2020) MenACWY vaccination implementation. We estimated VE in vaccine-eligible cases using the screening method. RESULTS: Overall, the IMD-W incidence rate declined by 61% (95% confidence interval [CI], 40 to 74). It declined by 82% (95% CI, 18 to 96) in the vaccine-eligible age group (individuals aged 15–36 months and 14–18 years) and by 57% (95% CI, 34 to 72) in vaccine-noneligible age groups. VE was 92% (95% CI, –20 to 99.5) in vaccine-eligible toddlers (aged 15–36 months). No IMD-W cases were reported in vaccine-eligible teenagers after the campaign. CONCLUSIONS: The MenACWY vaccination program was effective in preventing IMD-W in the target population. The IMD-W incidence reduction in vaccine-noneligible age groups may be caused by indirect effects of the vaccination program. However, disentangling natural fluctuation from vaccine effect was not possible. Our findings encourage the use of toddler and teenager MenACWY vaccination in national immunization programs.
format Online
Article
Text
id pubmed-9258937
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92589372022-07-07 Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study Ohm, Milou Hahné, Susan J M van der Ende, Arie Sanders, Elisabeth A M Berbers, Guy A M Ruijs, Wilhelmina L M van Sorge, Nina M de Melker, Hester E Knol, Mirjam J Clin Infect Dis Major Articles and Commentaries BACKGROUND: In response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for children aged 14 months was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting individuals aged 14–18 years was executed. We investigated the impact of MenACWY vaccination implementation in 2018–2020 on incidence rates and estimated vaccine effectiveness (VE). METHODS: We extracted IMD cases diagnosed between July 2014 and December 2020 from the national surveillance system. We calculated age group–specific incidence rate ratios by comparing incidence rates before (July 2017–March 2018) and after (July 2019–March 2020) MenACWY vaccination implementation. We estimated VE in vaccine-eligible cases using the screening method. RESULTS: Overall, the IMD-W incidence rate declined by 61% (95% confidence interval [CI], 40 to 74). It declined by 82% (95% CI, 18 to 96) in the vaccine-eligible age group (individuals aged 15–36 months and 14–18 years) and by 57% (95% CI, 34 to 72) in vaccine-noneligible age groups. VE was 92% (95% CI, –20 to 99.5) in vaccine-eligible toddlers (aged 15–36 months). No IMD-W cases were reported in vaccine-eligible teenagers after the campaign. CONCLUSIONS: The MenACWY vaccination program was effective in preventing IMD-W in the target population. The IMD-W incidence reduction in vaccine-noneligible age groups may be caused by indirect effects of the vaccination program. However, disentangling natural fluctuation from vaccine effect was not possible. Our findings encourage the use of toddler and teenager MenACWY vaccination in national immunization programs. Oxford University Press 2021-09-15 /pmc/articles/PMC9258937/ /pubmed/34525199 http://dx.doi.org/10.1093/cid/ciab791 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Articles and Commentaries
Ohm, Milou
Hahné, Susan J M
van der Ende, Arie
Sanders, Elisabeth A M
Berbers, Guy A M
Ruijs, Wilhelmina L M
van Sorge, Nina M
de Melker, Hester E
Knol, Mirjam J
Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
title Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
title_full Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
title_fullStr Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
title_full_unstemmed Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
title_short Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
title_sort vaccine impact and effectiveness of meningococcal serogroup acwy conjugate vaccine implementation in the netherlands: a nationwide surveillance study
topic Major Articles and Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258937/
https://www.ncbi.nlm.nih.gov/pubmed/34525199
http://dx.doi.org/10.1093/cid/ciab791
work_keys_str_mv AT ohmmilou vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy
AT hahnesusanjm vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy
AT vanderendearie vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy
AT sanderselisabetham vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy
AT berbersguyam vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy
AT ruijswilhelminalm vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy
AT vansorgeninam vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy
AT demelkerhestere vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy
AT knolmirjamj vaccineimpactandeffectivenessofmeningococcalserogroupacwyconjugatevaccineimplementationinthenetherlandsanationwidesurveillancestudy